Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention

Autoimmunity Reviews

Volumn 14, Issue 6, 2015, Pages 555-563

  Damoiseaux, Jan ^a   Andrade, Luis E ^b,e   Fritzler, Marvin J ^c   Shoenfeld, Yehuda ^d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CALGARY   (Canada)

^d SHEBA MEDICAL CENTER   (Israel)

^e Fleury   (Brazil)

Author keywords

Autoantibodies; Diagnosis; Harmonization; Standardization

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; CHOLINERGIC RECEPTOR ANTIBODY; MUSCLE ANTIBODY;

AUTOIMMUNE DISEASE; CLINICAL PRACTICE; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC INFLAMMATORY MYOSITIS; IMMUNOASSAY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEURONAL AUTOIMMUNE DISORDER; NOMENCLATURE; NONHUMAN; PREDICTION; PROGNOSIS; REVIEW; STANDARDIZATION; SYSTEMATIC REVIEW (TOPIC); WORKSHOP; ANIMAL; AUTOIMMUNE DISEASES; BRAZIL; IMMUNOLOGY; INFLAMMATION; ORGANIZATION;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; BIOMARKERS; BRAZIL; CONGRESSES AS TOPIC; HUMANS; INFLAMMATION; PROGNOSIS;

EID: 84933675856     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.01.017     Document Type: Review

References (122)

1. Comabella M., Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol 2014, 13:113-126.
2. Beck L.H., Bonegio R.G., Lambeau G., Beck D.M., Powell D.W., Cummins T.D., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361:11-21.
3. Schlumberger W., Hornig N., Lange S., Probst C., Komorowski L., Fechner K., et al. Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1. Autoimmun Rev 2014, 13:108-113.
4. Lancaster E., Dalmau J. Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 2012, 8:380-390.
5. Vincent A. Developments in autoimmune channelopathies. Autoimmun Rev 2013, 12:678-681.
6. Mehra S., Walker J., Patterson K., Fritzler M.J. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013, 12:340-354.
7. Lega J.C., Fabien N., Reynaud Q., Durieu I., Durupt S., Dutertre M., et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014, 13:883-891.
8. Iaccarino L., Ghirardello A., Bettio S., Zen M., Gatto M., Punzi L., et al. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun 2014, 48-49:122-127.
9. Roggenbuck D., Egerer K., von Landenberg P., Hiemann R., Feist E., Burmester G.R., et al. Antiphospholipid antibody profiling: time for a new technical approach?. Autoimmun Rev 2012, 11:821-826.
10. Verschuuren J.J., Huijbers M.G., Plomp J.J., Niks E.H., Molenaar P.C., Martinez-Martinez P., et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 2013, 12:918-923.
11. Mahler M., Miller F.W., Fritzler M.J. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 2014, 13:367-371.
12. Meroni P.L., Schur P.H. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010, 69:1420-1422.
13. Agmon-Levin N., Damoiseaux J., Kallenberg C., Sack U., Witte T., Herold M., et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014, 73:17-23.
14. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
15. Van den Hoogen F., Khanna D., Fransen J., Johnson S.R., Baron M., Tyndall A., et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013, 72:1747-1755.
16. Husby S., Koletzko S., Korponay-Szabó I.R., Mearin M.L., Phillips A., Shamir R., et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012, 54:136-160.
17. Graus F., Saiz A., Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010, 257:509-517.
18. Graus F., Dalmau J. Paraneoplastic neurological syndromes. Curr Opin Neurol 2012, 25:795-801.
19. Boronat A., Gelfand J.M., Gresa-Arribas N., Jeong H.Y., Walsh M., Roberts K., et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 2013, 73:120-128.
20. Sabater L., Gaig C., Gelpi E., Bataller L., Lewerenz J., Torres-Vega E., et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014, 13:575-586.
21. Höftberger R., Dalmau J., Graus F. Clinical neuropathology practice guide 5-2012: updated guideline for the diagnosis of antineuronal antibodies. Clin Neuropathol 2012, 31:337-341.
22. Tozzoli R., Bizzaro N. The clinical autoimmunologist and the laboratory autoimmunologist: the two sides of the coin. Autoimmun Rev 2012, 11:766-770.
23. Mahler M., Meroni P.L., Bossuyt X., Fritzler M.J. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res 2014, 2014:315179.
24. Bodoki L., Nagy-Vincze M., Griger Z., Betteridge Z., Szöllosi L., Dankó K. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 2014, 13:1211-1219.
25. Lahaye C., Beaufrére A.M., Boyer O., Drouot L., Soubrier M., Tournadre A. Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins. Joint Bone Spine 2014, 81:79-82.
26. Hamann P.D., Cooper R.G., McHugh N.J., Chinoy H. Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum". Autoimmun Rev 2013, 12:1177-1181.
27. Rönnelid J., Barbasso Helmers S., Storfors H., Grip K., Rönnblom L., Franck-Larsson K., et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 2009, 9:58-61.
28. Damoiseaux J.G., Tervaert J.W. The definition of autoimmune disease: are Koch's postulates applicable?. Neth J Med 2002, 60:266-268.
29. Mori S., Shigemoto K. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis. Autoimmun Rev 2013, 12:912-917.
30. Zhang B., Shen C., Bealmear B., Ragheb S., Xiong W.C., Lewis R.A., et al. Autoantibodies to agrin in myasthenia gravis patients. PLoS One 2014, 9:e91816.
31. Gallardo E., Martínez-Hernández E., Titulaer M.J., Huijbers M.G., Martínez M.A., Ramos A., et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev 2014, 13:1003-1007.
32. Drori T., Chapman J. Diagnosis and classification of neuromyelitis optica (Devic's syndrome). Autoimmun Rev 2014, 13:531-533.
33. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003, 349:139-145.
34. Derfuss T., Meinl E. Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?. Curr Opin Neurol 2012, 25:231-238.
35. Srivastava R., Aslam M., Kalluri S.R., Schirmer L., Buck D., Tackenberg B., et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012, 367:115-123.
36. Brickshawana A., Hinson S.R., Romero M.F., Lucchinetti C.F., Guo Y., Buttmann M., et al. Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol 2014, 13:795-806.
37. de Bock L., Somers K., Fraussen J., Hendriks J.J., van Horssen J., Rouwette M., et al. Sperm-associated antigen 16 is a novel target of the humoral autoimmune response in multiple sclerosis. J Immunol 2014, 193:2147-2156.
38. Fraussen J., Claes N., de Bock L., Somers V. Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev 2014, 13:1126-1137.
39. Chan E.K., Fritzler M.J., Wiik A., Andrade L.E., Reeves W.H., Tincani A., et al. AutoAbSC.Org - Autoantibody Standardization Committee in 2006. Autoimmun Rev 2007, 6:577-580.
40. Shoenfeld Y., Cervera R., Haass M., Kallenberg C., Khamashta M., Meroni P., et al. EASI - The European Autoimmunity Standardisation Initiative: a new initiative that can contribute to agreed diagnostic models of diagnosing autoimmune disorders throughout Europe. Ann N Y Acad Sci 2007, 1109:138-144.
41. Damoiseaux J., Tervaert J.W., Derksen R., Hamann D., Hooijkaas H., Klasen I., et al. Autoantibody standardization in The Netherlands. Ann N Y Acad Sci 2009, 1173:10-14.
42. Sack U., Conrad K., Csernok E., Frank I., Hiepe F., Krieger T., et al. Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann N Y Acad Sci 2009, 1173:166-173.
43. Damoiseaux J., Agmon-Levin N., Van Blerk M., Chopyak V., Eriksson C., Heijnen I., et al. From ANA-screening to antigen-specificity: an EASI-survey on the daily practice in European countries. Clin Exp Rheumatol 2014, 32:539-546.
44. Meroni P.L., Biggioggero M., Pierangeli S.S., Sheldon J., Zegers I., Borghi M.O. Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. Nat Rev Rheumatol 2014, 10:35-43.
45. Bossuyt X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009, 8:543-548.
46. Francescantonio P.L., Cruvinel Wde M., Dellavance A., Andrade L.E., Taliberti B.H., von Mühlen C.A., et al. IV Brazilian guidelines for autoantibodies on HEp-2 cells. Rev Bras Reumatol 2014, 54:44-50.
47. Wiik A.S., Høier-Madsen M., Forslid J., Charles P., Meyrowitsch J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 2010, 35:276-290.
48. Mariz H.A., Sato E.I., Barbosa S.H., Rodrigues S.H., Dellavance A., Andrade L.E. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011, 63:191-200.
49. Mahler M., Hanly J.G., Fritzler M.J. Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev 2012, 11:642-645.
50. Bizzaro N., Antico A., Platzgummer S., Tonutti E., Bassetti D., Pesente F., et al. Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems. Autoimmun Rev 2014, 13:292-298.
51. Mahler M., Pierangeli S., Meroni P.L., Fritzler M.J. Autoantibodies in systemic autoimmune disorders. J Immunol Res 2014, 2014:263091.
52. Vermeersch P., Bossuyt X. Prevalence and clinical significance of rare antinuclear antibody patterns. Autoimmun Rev 2013, 12:998-1003.
53. Dellavance A., Gallindo C., Soares M.G., da Silva N.P., Mortara R.A., Andrade L.E. Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern. Rheumatology (Oxford) 2009, 48:632-637.
54. Dellavance A., Alvarenga R.R., Rodrigues S.H., Barbosa S.H., Camilo A.C., Shiguedomi H.S., et al. Autoantibodies to 60kDa SS-A/Ro yield a specific nuclear myriad discrete fine speckled immunofluorescence pattern. J Immunol Methods 2013, 390:35-40.
55. Bizzaro N., Tozzoli R., Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases?. Arthritis Rheum 2007, 56:1736-1744.
56. Harel M., Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality?. Ann N Y Acad Sci 2006, 1069:322-345.
57. Shepshelovich D., Shoenfeld Y. Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity. Lupus 2006, 15:183-190.
58. Lahmer T., Heemann U. Anti-glomerular basement membrane antibody disease: a rare autoimmune disorder affecting the kidney and the lung. Autoimmun Rev 2012, 12:169-173.
59. Damoiseaux J. Bullous skin diseases: classical types of autoimmune diseases. Scientifica (Cairo) 2013, 2013:457982.
60. Hu Z.D., Deng A.M. Autoantibodies in pre-clinical autoimmune disease. Clin Chim Acta 2014, 437:14-18.
61. Mitchison H.C., Bassendine M.F., Hendrick A., Bennett M.K., Bird G., Watson A.J., et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?. Hepatology 1986, 6:1279-1284.
62. Metcalf J.V., Mitchison H.C., Palmer J.M., Jones D.E., Bassendine M.F., James O.F. Natural history of early primary biliary cirrhosis. Lancet 1996, 348:1399-1402.
63. Jones D.E. Autoantigens in primary biliary cirrhosis. J Clin Pathol 2000, 53:813-821.
64. Kulmala P., Savola K., Petersen J.S., Vähäsalo P., Karjalainen J., Löppönen T., et al. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest 1998, 101:327-336.
65. Ziegler A.G., Hummel M., Schenker M., Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999, 48:460-468.
66. Sosenko J.M., Skyler J.S., Palmer J.P., Krischer J.P., Yu L., Mahon J., et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care 2013, 36:2615-2620.
67. Martin S., Wolf-Eichbaum D., Duinkerken G., Scherbaum W.A., Kolb H., Noordzij J.G., et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001, 345:1036-1040.
68. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
69. Rantapää-Dahlqvist S., de Jong B.A., Berglin E., Hallmans G., Wadell G., Stenlund H., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749.
70. Nielen M.M., van Schaardenburg D., Reesink H.W., van de Stadt R.J., van der Horst-Bruinsma I.E., de Koning M.H., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-386.
71. Jonsson R., Theander E., Sjöström B., Brokstad K., Henriksson G. Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA 2013, 310:1854-1855.
72. Rijkers G.T., Damoiseaux J.G., Hooijkaas H. Medical immunology: two-way bridge connecting bench and bedside. Immunol Lett 2014, 162:127-133.
73. Dellavance A., Cançado E.L., Abrantes-Lemos C.P., Harriz M., Marvulle V., Andrade L.E. Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis. Hepatol Int 2012, 7:775-784.
74. Sokolove J., Bromberg R., Deane K.D., Lahey L.J., Derber L.A., Chandra P.E., et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 2012, 7:e35296.
75. Damoiseaux J. Autoantibodies in the grocery shop: does quantity matter?. Immunol Res 2013, 56:413-419.
76. Kavanaugh A.F., Solomon D.H., American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 2002, 47:546-555.
77. Reveille J.D. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus 2004, 13:290-297.
78. Tomasson G., Grayson P.C., Mahr A.D., Lavalley M., Merkel P.A. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis. Rheumatology (Oxford) 2012, 51:100-109.
79. Kallenberg C.G. Anti-C1q autoantibodies. Autoimmun Rev 2008, 7:612-615.
80. Kemna M.J., Damoiseaux J., Austen J., Winkens B., Peters J., van Paassen P., et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol Oct 16 2014, [pii: ASN.2013111233, Epub ahead of print].
81. Kivity S., Agmon-Levin N., Blank M., Shoenfeld Y. Infections and autoimmunity-friends or foes?. Trends Immunol 2009, 30:409-414.
82. Agmon-Levin N., Theodor E., Segal R.M., Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol 2013, 45:256-266.
83. Wilde B., van Paassen P., Witzke O., Tervaert J.W. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 2011, 79:599-612.
84. Peelen E., Knippenberg S., Muris A.H., Thewissen M., Smolders J., Tervaert J.W., et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev 2011, 10:733-743.
85. Smolders J., Damoiseaux J. Vitamin D as a T-cell modulator in multiple sclerosis. Vitam Horm 2011, 86:401-428.
86. Fujimoto M. Myositis-specific autoantibodies. Brain Nerve 2013, 65:449-460.
87. Hamaguchi Y., Kodera M., Matsushita T., Hasegawa M., Inaba Y., Usuda T., et al. Clinical and immunological predictors of scleroderma renal crisis for Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol 2014, 10.1002/art.38994.
88. Zisimopoulou P., Brenner T., Trakas N., Tzartos S.J. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013, 12:924-930.
89. Kershenovich R., Hodak E., Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev 2014, 13:477-481.
90. Schoels M., Bombardier C., Aletaha D. Diagnostic and prognostic value of antibodies and soluble biomarkers in undifferentiated peripheral inflammatory arthritis: a systematic review. J Rheumatol Suppl 2011, 87:20-25.
91. Schulte-Pelkum J., Fritzler M., Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009, 8:632-637.
92. Montano-Loza A.J., Shums Z., Norman G.L., Czaja A.J. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012, 32:85-92.
93. Franssen C.F., Stegeman C.A., Kallenberg C.G., Gans R.O., De Jong P.E., Hoorntje S.J., et al. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int 2000, 57:2195-2206.
94. Rutgers A., Heeringa P., Damoiseaux J.G., Tervaert J.W. ANCA and anti-GBM antibodies in diagnosis and follow-up of vasculitic disease. Eur J Intern Med 2003, 14:287-295.
95. Agmon-Levin N., Mosca M., Petri M., Shoenfeld Y. Systemic lupus erythematosus one disease or many?. Autoimmun Rev 2012, 11:593-595.
96. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
97. Petri M., Orbai A.M., Alarcón G.S., Gordon C., Merrill J.T., Fortin P.R., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012, 64:2677-2686.
98. Sherer Y., Gorstein A., Fritzler M.J., Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004, 34:501-537.
99. Rekvig O.P., Putterman C., Casu C., Gao H.X., Ghirardello A., Mortensen E.S., et al. Autoantibodies in lupus: culprits or passive bystanders?. Autoimmun Rev 2012, 11:596-603.
100. Trouw L.A., Groeneveld T.W., Seelen M.A., Duijs J.M., Bajema I.M., Prins F.A., et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004, 114:679-688.
101. Hanly J.G., Urowitz M.B., Siannis F., Farewell V., Gordon C., Bae S.C., et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008, 58:843-853.
102. Karassa F.B., Afeltra A., Ambrozic A., Chang D.M., De Keyser F., Doria A., et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006, 54:312-324.
103. Ghirardello A., Briani C., Lucchetta M., Doria A. Anti-ribosomal P protein antibodies and neuropsychiatric systemic lupus erythematosus: cross-sectional vs. prospective studies. Lupus 2010, 19:771-773.
104. Hanly J.G., Urowitz M.B., Su L., Bae S.C., Gordon C., Clarke A., et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011, 70:1726-1732.
105. McClain M.T., Arbuckle M.R., Heinlen L.D., Dennis G.J., Roebuck J., Rubertone M.V., et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004, 50:1226-1232.
106. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
107. Bertolaccini M.L., Amengual O., Andreoli L., Atsumi T., Chighizola C.B., Forastiero R., et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014, 13:917-930.
108. de Jesus G.R., Agmon-Levin N., Andrade C.A., Andreoli L., Chighizola C.B., Porter T.F., et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014, 13:795-813.
109. Brucato A., Cimaz R., Caporali R., Ramoni V., Buyon J. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2011, 40:27-41.
110. Gordon P., Khamashta M.A., Rosenthal E., Simpson J.M., Sharland G., Brucato A., et al. Anti-52kDa Ro, anti-60kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol 2004, 31:2480-2487.
111. Spence D., Hornberger L., Hamilton R., Silverman E.D. Increased risk of complete congenital heart block in infants born to women with hypothyroidism and anti-Ro and/or anti-La antibodies. J Rheumatol 2006, 33:167-170.
112. Jaeggi E., Laskin C., Hamilton R., Kingdom J., Silverman E. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol 2010, 55:2778-2784.
113. DeNardo D.G., Coussens L.M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007, 9:212.
114. Kobold S., Luetkens T., Cao Y., Bokemeyer C., Atanackovic D. Prognostic and diagnostic value of spontaneous tumor-related antibodies. Clin Dev Immunol 2010, 2010:721531.
115. van Leeuwen M., Damoiseaux J., Duijvestijn A., Tervaert J.W. The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis. Autoimmun Rev 2009, 9:53-57.
116. Witte T. IgM antibodies against dsDNA in SLE. Clin Rev Allergy Immunol 2008, 34:345-347.
117. Grönwall C., Akhter E., Oh C., Burlingame R.W., Petri M., Silverman G.J. IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. Clin Immunol 2012, 142:390-398.
118. Schulz R., Werner B., Behn U. Self-tolerance in a minimal model of the idiotypic network. Front Immunol 2014, 5:86.
119. Menshikov I., Beduleva L., Frolov M., Abisheva N., Khramova T., Stolyarova E., et al. The idiotypic network in the regulation of autoimmunity: theoretical and experimental studies. J Theor Biol 2014, [pii: S0022-5193(14)00592-X, Epub ahead of print]. 10.1016/j.jtbi.2014.10.003.
120. Pratesi F., Petit Teixeira E., Sidney J., Michou L., Puxeddu I., Sette A., et al. HLA shared epitope and ACPA: just a marker or an active player?. Autoimmun Rev 2013, 12:1182-1187.
121. Alberici F., Martorana D., Bonatti F., Gioffredi A., Lyons P.A., Vaglio A. Genetics of ANCA-associated vasculitides: HLA and beyond. Clin Exp Rheumatol 2014, 32(Suppl. 82):S90-S97.
122. Perricone C., Colafrancesco S., Mazor R.D., Soriano A., Agmon-Levin N., Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun 2013, 47:1-16.